3,938 Shares in Ascendis Pharma A/S $ASND Bought by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,938 shares of the biotechnology company’s stock, valued at approximately $901,000.

Other hedge funds also recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP bought a new position in shares of Ascendis Pharma A/S during the third quarter worth about $15,693,000. Nomura Asset Management Co. Ltd. lifted its position in Ascendis Pharma A/S by 57.5% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company’s stock valued at $9,319,000 after purchasing an additional 15,950 shares during the last quarter. Braun Stacey Associates Inc. boosted its stake in Ascendis Pharma A/S by 26.8% during the 4th quarter. Braun Stacey Associates Inc. now owns 119,095 shares of the biotechnology company’s stock valued at $25,396,000 after purchasing an additional 25,148 shares during the period. Candriam S.C.A. boosted its stake in Ascendis Pharma A/S by 23.2% during the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock valued at $52,671,000 after purchasing an additional 43,338 shares during the period. Finally, UBS Group AG boosted its stake in Ascendis Pharma A/S by 57.9% during the 4th quarter. UBS Group AG now owns 308,190 shares of the biotechnology company’s stock valued at $65,718,000 after purchasing an additional 112,986 shares during the period.

Analyst Ratings Changes

ASND has been the topic of several analyst reports. Wedbush restated an “outperform” rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Barclays boosted their price objective on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Citigroup assumed coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Finally, Wells Fargo & Company cut their target price on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $295.67.

Insider Transactions at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jean Jacques Bienaime bought 400 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director directly owned 400 shares in the company, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Trading Down 3.3%

Shares of Ascendis Pharma A/S stock opened at $259.80 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The firm has a market cap of $16.21 billion, a price-to-earnings ratio of 29.97 and a beta of 0.37. The business has a fifty day simple moving average of $242.44 and a 200-day simple moving average of $231.81. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 4.63 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.